Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
The objective of this review was to investigate the efficacy, effectiveness and safety of HPV vaccination in women undergoing conisation compared with those not receiving a HPV vaccination.
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
The purpose of this scoping review is to describe and summarise the rationale behind and methodological approaches used to conduct cascade-of-care analyses for TB infection in low-TB incidence countries.
This guidance outlines key strategic and operational considerations to inform pandemic preparedness planning round the design and implementation of public health and social measures in community settings in the EU/EEA.
At the request of the Slovenian National Institute of Public Health (NIJZ), ECDC designed and facilitated an After-Action review (AAR), focusing on the response to the COVID-19 pandemic.
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
This protocol describes the common methodology to be applied to established health data registries across seven participating EU/EEA Member States to estimate vaccine effectiveness for Coronavirus disease 2019 (COVID-19) in children and adolescents aged 5-17 years old.
In 2023, significant increases in the number of measles cases and outbreaks were observed globally, including in 40 of the 53 countries of the European region, and in at least ten EU/EEA countries.
This protocol presents a common updated methodology to estimate vaccine effectiveness (VE) for COVID-19, using established health data registries in participating European Union and European Economic Area (EU/EEA) countries.